Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHAMP-UK: Low-dose Atropine for Myopia
NCT03690089Phase 2Active, not recruiting
- Sponsor
- Belfast Health and Social Care Trust
- Start
- Apr 2019
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Myopine in myopia (2 arms), sponsored by Belfast Health and Social Care Trust. Primary endpoint: Spherical equivalent refractive error (myopia severity) at 24 months. Started Apr 2019; status: active, not recruiting.
02
Drugs
Myopine
03
Conditions
myopia
Beyond the preview
Go deeper on NCT03690089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03690089.